MedTrace Logo

A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)

NCT07684612 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 690

Last updated 2026-07-15

No results posted yet for this study

Summary

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) in combination with bevacizumab works in treating platinum-sensitive ovarian cancer compared to standard treatments by checking whether it makes cancers smaller or disappear completely and if it helps participants live longer. The study also assesses whether Mo-Rez in combination with bevacizumab is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of Mo-Rez.

Conditions

  • Ovarian Neoplasms

Interventions

DRUG

Mocertatug rezetecan (Mo-Rez)

Mocertatug rezetecan will be administered

DRUG

Carboplatin

Carboplatin will be administered

DRUG

Paclitaxel

Paclitaxel will be administered

DRUG

Gemcitabine

Gemcitabine will be administered

DRUG

Pegylated liposomal doxorubicin (PLD)

PLD will be administered

DRUG

Bevacizumab

Bevacizumab will be administered

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-22
Primary Completion
2030-05-21
Completion
2033-04-22
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07684612 on ClinicalTrials.gov